Robotic-arm-assisted versus conventional total knee replacement (RACER-Knee): a pragmatic, multicentre, participant-masked and assessor-masked, superiority, randomised controlled trial
Source: View publication →
In patients with advanced knee osteoarthritis, robotic-arm-assisted total knee replacement did not improve joint awareness or functional outcomes at 12 months compared to conventional surgery, while adding operative time and procedural costs.
Key Findings
Study Design
Study Limitations
Clinical Significance
The RACER-Knee trial provides rigorous Level I evidence challenging the widespread commercial claims that robotic-assisted knee arthroplasty yields superior early functional recovery. While robotic systems reliably improve radiographic precision, this technological advantage does not translate into tangible, patient-reported benefits regarding joint awareness or pain at 1 year. Consequently, healthcare systems and orthopedic centers must critically weigh the lack of early clinical superiority against the substantial capital investments, per-case costs, and increased operative times associated with routine robotic use.
Historical Context
Over the past decade, robotic-arm-assisted joint replacement has experienced explosive growth and aggressive marketing, achieving massive global market penetration (utilized in over 40% of cases in Australia and nearly 20% in the US by 2026). Proponents argued that millimeter-level precision in implant positioning and dynamic soft-tissue balancing would fundamentally improve clinical outcomes, addressing the historical 15-20% patient dissatisfaction rate in conventional knee arthroplasty. Prior to RACER-Knee, the literature was largely composed of observational cohorts, retrospective reviews, or small, unblinded trials subject to heavy placebo effects. As the largest participant- and assessor-masked randomized controlled trial in this space—employing sham marker incisions to maintain blinding—RACER-Knee serves as a landmark reality check, highlighting the dissociation between technical precision and actual patient-perceived benefits.
Guided Discussion
High-yield insights from every perspective
What is the primary pathophysiological indication for total knee replacement, and what is the theoretical mechanism by which robotic-arm assistance was hypothesized to improve postoperative joint awareness?
Key Response
Total knee replacement is indicated for end-stage knee osteoarthritis refractory to conservative management, characterized by cartilage loss, osteophyte formation, and joint space narrowing. Robotic assistance was theoretically hypothesized to improve outcomes by providing sub-millimeter precision in bone cuts and improved soft tissue balancing, which surgeons believed would result in a more natural feeling knee and decreased joint awareness, though the RACER-Knee trial proved this does not translate to clinical superiority at 12 months.
How should you counsel a patient with severe knee osteoarthritis who specifically requests robotic-assisted total knee replacement because they saw an advertisement claiming it provides a faster, less painful recovery?
Key Response
Residents must practice evidence-based patient counseling. Based on the Level I evidence from the RACER-Knee trial, the patient should be informed that while robotic-assisted surgery is safe, it does not provide superior functional outcomes, better pain relief, or improved joint awareness at 12 months compared to conventional methods, and it is associated with longer operative times and higher procedural costs.
While the RACER-Knee trial demonstrated no difference in functional outcomes at 12 months, how might the improved radiographic accuracy and implant alignment typically achieved with robotic assistance impact the 10- to 15-year survivorship of the prosthesis?
Key Response
Fellows must distinguish between short-term functional outcomes and long-term mechanical survival. While 12-month patient-reported outcomes show no difference, improved coronal and sagittal alignment might reduce eccentric wear and aseptic loosening over decades. Therefore, the true value of robotic assistance may only become apparent in long-term registry data regarding revision rates, rather than early functional recovery.
Given that the superiority design of the RACER-Knee trial failed to show clinical benefit at 12 months while demonstrating increased operative time and procedural costs, how do you justify the continued capital investment and institutional utilization of robotic systems in a value-based healthcare model?
Key Response
Attendings must balance clinical evidence with hospital economics and market dynamics. This question highlights the tension between empirical evidence showing a lack of short-term clinical superiority and external pressures like market competition and patient demand. It emphasizes the need for critical value analysis before institutional adoption of expensive new technologies that add procedural time without improving early patient outcomes.
Scholarly Review
Critical appraisal through the lens of expert reviewers and guideline development
The RACER-Knee trial utilized participant and assessor masking but could not mask the operating surgeons. How does this partial masking, combined with a pragmatic, multicentre superiority design, influence the risk of performance bias and the interpretation of patient-reported primary outcomes?
Key Response
Surgical trials face inherent challenges with masking. Unmasked surgeons might alter their postoperative care, rehabilitation protocols, or surgical speed based on their enthusiasm for the technology. While the use of a patient-reported outcome with participant masking helps mitigate placebo effects, surgeon-induced subtle biases in perioperative protocols could still theoretically occur, making rigorous assessor masking and objective secondary endpoints crucial for trial validity.
As a peer reviewer, how would you critically evaluate the decision to use a 12-month primary endpoint for assessing the superiority of robotic-assisted total knee replacement, and what potential threats does this timeline pose to the definitive conclusion that the technology lacks clinical utility?
Key Response
A rigorous reviewer would argue that while 12 months is sufficient for assessing acute recovery and early functional plateau, it is completely inadequate for detecting differences in implant longevity or late-stage revisions, which are the primary theoretical benefits of micromillimeter precision. Publishing this as a definitive negative trial requires careful editorial framing to avoid over-extrapolating short-term equivalence to long-term parity.
How should the results of the RACER-Knee trial influence upcoming orthopedic clinical practice guidelines (such as those by the AAOS or NICE) regarding recommendations for the routine use of robotic assistance in total knee arthroplasty?
Key Response
Guideline committees rely on high-quality RCTs to establish standards of care. The RACER-Knee trial provides Level I evidence that robotic assistance should not be recommended as a routine standard of care over conventional TKA for the purpose of short-term functional gains, due to increased cost and operative time without clinical benefit. Guidelines should reflect a strong recommendation that conventional TKA remains the gold standard, while noting that long-term survivorship data for robotics is still pending.
Clinical Landscape
Noteworthy Related Trials
Song et al. RCT
Tested
Active robotic-assisted TKA
Population
Patients with severe knee osteoarthritis
Comparator
Conventional manual TKA
Endpoint
Mechanical axis alignment and implant positioning
Kayani et al. Prospective Study
Tested
Robotic-arm assisted TKA (Mako)
Population
Patients undergoing primary TKA for osteoarthritis
Comparator
Conventional jig-based TKA
Endpoint
Early functional recovery and hospital discharge time
Batailler et al. RCT
Tested
Robotic-arm assisted TKA
Population
Patients with end-stage knee osteoarthritis
Comparator
Conventional TKA
Endpoint
Clinical outcomes (Knee Society Score) and radiological accuracy
Tailored to your role
Want this tailored to you?
Add your specialty or training stage to get role-specific takeaways and more questions.
Personalize this analysis